Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Canadian-Australasian Randomised Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease
University of British Columbia
3,306 participants
Dec 1, 2018
INTERVENTIONAL
Conditions
Summary
The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse Cardiac Events. Secondary analyses will assess the impact of screening on the rate of transplantation, and the relative cost-effectiveness of screening.
Eligibility
Inclusion Criteria5
- adults aged 18 years of age or older
- Dialysis-dependent kidney failure and currently being assessed for OR active on the kidney transplant waiting list
- expected to require further screening for CAD prior to transplantation (by current standard of care);
- able to give consent;
- anticipated to undergo transplantation more than 12 months from date of enrolment
Exclusion Criteria6
- patients with signs or symptoms suggestive of uncontrolled cardiac disease such as unstable coronary syndromes, decompensated heart failure, uncontrolled arrhythmia, and severe valvular heart disease;
- patients who "on-hold" for transplantation due to a medical problem;
- patients with other solid organ transplants;
- multi-organ transplant candidates (e.g. kidney-pancreas transplant candidates);
- patients with planned living donor transplant;
- patients unable to give consent.
Interventions
No further screening for asymptomatic coronary artery disease after wait-list entry
Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03674307